TibaRay, a Stanford spinout, has launched a Regulation CF campaign on Wefunder, opening its investment opportunity to individual investors. The company is developing next-generation accelerator technology designed to enable FLASH radiotherapy, a treatment modality that delivers radiation hundreds of times faster than current systems. Research suggests that this ultrafast delivery may reduce damage to healthy tissue while maintaining tumor control, potentially transforming cancer care.
Founded on decades of accelerator and medical physics research, TibaRay has secured over $27 million in funding, including more than $14 million in non-dilutive federal research grants. The company holds more than 20 issued and pending patents related to next-generation radiotherapy systems. Its proprietary Galactica linear accelerator has already been integrated into Leo Cancer Care’s upright radiotherapy system, marking the first commercial adoption of TibaRay’s platform.
TibaRay is pursuing a phased commercialization strategy. In the near term, it generates revenue by selling its accelerator technology into medical and adjacent markets such as imaging, security scanning, and non-destructive testing. The long-term goal is deployment of the PHASER radiotherapy system designed for ultrafast treatment delivery. The Wefunder campaign provides individual investors an opportunity to participate in this next phase of development.
Investors can review the full campaign details, including technology specifics, partnerships, and development plans, on the TibaRay campaign page. The campaign is open to non-accredited investors under Regulation Crowdfunding, allowing broader public participation in a company traditionally accessible only to venture capital and institutional investors.
The implications of this announcement are significant. FLASH radiotherapy could address a critical limitation of conventional radiation therapy: damage to surrounding healthy tissue. By enabling treatment in a fraction of a second, TibaRay’s technology may improve patient outcomes and expand treatment options for cancers currently considered inoperable or radiation-resistant. The company’s approach also leverages upright patient positioning, which could reduce costs and improve access compared to traditional prone or supine systems.
With the launch of the Wefunder campaign, TibaRay aims to accelerate development and move closer to clinical trials. The company’s combination of federal funding, strong intellectual property, and commercial partnerships suggests a credible path toward commercialization. For investors, the campaign offers a chance to support a potentially disruptive medical technology at an early stage. However, as with any early-stage investment, risks include technical challenges, regulatory hurdles, and market adoption uncertainties.
